Clinical operations solution company Slope has raised $20m in a Series A funding round led by international venture capital firm New Enterprise Associates (NEA) to expedite go-to-market efforts and further progress into decentralised and direct-to-patient clinical trials.
The technology-powered infrastructure solution of Slope links ClinOps teams, research sites, contract research organisations (CROs), vendors, patients and labs, in real-time.
This connection is facilitated through a 21 CFR Part 11 compliant software platform, obtaining clinical supply chain demand data at the patient level.
The data can be used along with research-oriented workflows for operational complexity coordination and automation.
Slope CEO and co-founder Rust Felix said: “Finding an investment partner with first-hand knowledge of the problems caused by the inefficiencies of current clinical trial supply chain management processes was a key success factor for us at Slope.
“With its expansive life sciences portfolio and deep domain expertise, NEA was at the top of our list.”
Slope’s solution tackles the operational setbacks and delays caused by manual, spreadsheet-powered clinical trial management processes.
Software-aided workflows steered by real-time supply chain data automatically organise thousands of logistical transactions that happen throughout the trial lifecycle while obtaining and recording significant metadata.
This guarantees a completely traceable chain of custody, irrespective of the trial design, for all therapies, devices, lab kits, samples and equipment as they move across a supply chain of the trial.
In 2018, the company unveiled its free inventory management solution for clinical research sites.
A solution was launched in 2019 for clinical trial sponsors and CROs that links clinical operations groups to operational data happening at the patient level.
This year, Slope launched a fulfilment centre in Richmond, Virginia, US, producing smart lab kits that aid in real-time inventory management.